An FDA advisory committee voted narrowly on July 23, 2026, to recommend that compounding pharmacies gain access to several popular peptide compounds, including BPC-157, KPV, TB-500, and MOTS-C, overriding explicit objections from the FDA's own career scientists and sparking an audible gasp in the meeting room when the tally was announced.
The Pharmacy Compounding Advisory Committee voted 8 to 6 in favor of recommending BPC-157 and KPV for the 503A bulks list, which governs what substances compounding pharmacies may legally produce. The committee also voted in favor of MOTS-C and TB-500. The vote is not binding. The FDA will ultimately make the final regulatory decision through a formal rulemaking process, and the agency has gone against advisory panel recommendations before.
